e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Phenotyping and monitoring of airway diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Investigating change in the COPD assessment test (CAT) within α-1 antitrypsin deficiency (A1ATD)
R. Edgar, D. Griffiths, E. Sapey, R. Stockley (Birmingham, United Kingdom)
Source:
Annual Congress 2011 - Phenotyping and monitoring of airway diseases
Session:
Phenotyping and monitoring of airway diseases
Session type:
Poster Discussion
Number:
3514
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Edgar, D. Griffiths, E. Sapey, R. Stockley (Birmingham, United Kingdom). Investigating change in the COPD assessment test (CAT) within α-1 antitrypsin deficiency (A1ATD). Eur Respir J 2011; 38: Suppl. 55, 3514
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Association between alpha1 antitrypsin (AAT) circulating polymers (CP) and lung and liver disease in patients with AAT deficiency (AATD).
Source: Virtual Congress 2021 – Molecular pathology and cell biology of pulmonary diseases
Year: 2021
CT scan derived emphysema scores correlate with spirometry and gas exchange but not acute exacerbation rates (AER) or COPD assessment test (CAT) in COPD subjects with and without alpha-1-antitrypsin (AAT) deficiency
Source: Annual Congress 2013 –Monitoring lung function in airway diseases
Year: 2013
COPD assessment test (CAT) in the evaluation of COPD
Source: Annual Congress 2012 - COPD: epidemiology and varia
Year: 2012
Aα360: A measure of disease and treatment efficacy in alpha-1-antitrypsin (A1AT) deficiency
Source: Annual Congress 2010 - COPD: phenotyping and monitoring
Year: 2010
Is the COPD assessment test (CAT) useful in our patients?
Source: Annual Congress 2012 - Diagnostic insights and decision making in primary care
Year: 2012
The results of alpha-1 antitrypsine (AAT) phenotyping in patients with COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 260s
Year: 2002
Patterns of exacerbations in alpha 1 antitrypsin deficiency (AATD)
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
Relationship between COPD assessment test (CAT) and declines of lung function in COPD patients
Source: Annual Congress 2012 - COPD: epidemiology and varia
Year: 2012
Reduction in incidence of exacerbations in patients with alpha 1 antitrypsin deficiency (A1ATD) treated with concentrates of alpha 1 antitrypsin (A1AT): REXA study
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011
Intra-epithelial polymerization, accumulation and secretion of alpha
1
antitrypsin (AAT) Z polymers in the lung of patients with alpha-1 antitrypsin deficiency (AATD)
Source: Annual Congress 2010 - Epithelial cell biology
Year: 2010
Effects of double dose alpha 1 antitrypsin (AAT) therapy on cytokine pathways in AAT Deficiency (AATD)
Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond
Year: 2018
Functional alterations of small airways in patients with alpha-1 antitrypsin deficiency (AATD) in a longitudinal study
Source: Eur Respir J 2005; 26: Suppl. 49, 361s
Year: 2005
Predicting clinical course of alpha 1 anti-trypsin deficiency (AATD) using GOLD 2011 classification
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
Prevalence of alpha-1-antitrypsin deficiency (A1AD) in patients with COPD.
Source: Virtual Congress 2021 – COPD burden, epidemiology and management
Year: 2021
CAT (COPD assessment test) as outcome parameter of pulmonary rehabilitation (PR) in COPD
Source: Annual Congress 2011 - What do individuals know about their disease? Educational needs, the psychological impact of chronic respiratory disease and health-related quality of life
Year: 2011
Alpha 1 antitrypsin (A1AT) deficiency in children with asthma in Brazil
Source: Eur Respir J 2003; 22: Suppl. 45, 499s
Year: 2003
The use of impulse oscillometry (IOS) in the differentiation of bronchiectasis and emphysema in patients with alpha
1
antitrypsin deficiency (α
1
-ATD)
Source: Annual Congress 2004 - Airway resistance: application and technique
Year: 2004
Long-term changes in the COPD assessment test (CAT) after pulmonary rehabilitation
Source: Annual Congress 2011 - What do individuals know about their disease? Educational needs, the psychological impact of chronic respiratory disease and health-related quality of life
Year: 2011
Frequency of α-1 antitrypsin deficiency (AATD) in a population screening in an high risk area (Val Trompia, Italy)
Source: Eur Respir J 2006; 28: Suppl. 50, 453s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept